NVS earnings: next report 2026-10-27, real EPS beat/miss history, analyst consensus Hold, P/E 23.23. Updated 2026-07-23.
Novartis (NVS) Research Hub
Novartis (NVS) trades on NYSE, CH in the Healthcare (Drug Manufacturers - General) sector. As of 2026-09-11, shares last closed at 137.16 USD (-0.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 23.23, market cap 291.98B. This hub links to the full technical, earnings and options research available for NVS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NYSE, CH |
| Last close | 137.16 USD (-0.23%) |
| 52-week range | 137.01 USD – 164.48 USD |
| Trend regime | Range |
| 14-day RSI | 33.2 (Bearish) |
| Trailing P/E | 23.23 |
| Market cap | 291.98B |
| Dividend yield | 2.97% |
| Next earnings | 2026-10-27 |
Available research for NVS
Covered Call on NVS: how it works, illustrative setup around the real 137.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVS: how it works, illustrative setup around the real 137.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVS: how it works, illustrative setup around the real 137.16 USD price, max profit/loss, breakeven and when to use it. Educational.
NVS technical analysis: range, last 137.16 USD, RSI 33.2, 52w range 137.01 USD–164.48 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NVS in?
Novartis (NVS) is classified under Healthcare (Drug Manufacturers - General), listed on NYSE, CH.
Is NVS in an uptrend or downtrend?
As of 2026-09-11, NVS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVS's trailing P/E ratio?
NVS's trailing P/E is 23.23, with a market cap of 291.98B. See the earnings research page for full valuation detail.
When does NVS next report earnings?
NVS is next scheduled to report earnings on 2026-10-27, with a consensus EPS estimate of 2.26 USD.